Clinical Trials List
2025-04-01 - 2029-09-30
Recruiting8
ICD-10N05.9
Unspecified nephritic syndrome with unspecified morphologic changes
ICD-10N06.9
Isolated proteinuria with unspecified morphologic lesion
ICD-10N07.9
Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions
ICD-10N15.9
Renal tubulo-interstitial disease, unspecified
ICD-9583.9
Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/10
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yueh-Lin Wu Division of Nephrology
- Tso-Hsiao Chen Division of Nephrology
- Chung-Te Liu Division of Nephrology
- 楊韻紅 Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Cheng-Chia Lee Division of Nephrology
- Ya-Chung Tian Division of Nephrology
- Kun-Hua Tu Division of Nephrology
- Wen-Hung Huang Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林冠宏 Division of Nephrology
- YUNG-HO HSU Division of Nephrology
- 洪冠予 Division of Nephrology
- Chia-Te Liao Division of Nephrology
- Mei-Yi Wu Division of Nephrology
- Li-Yee Hong Division of Nephrology
- Cai-Mei Zheng Division of Nephrology
- I-WEN WU Division of Nephrology
- 高芷華 Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Biopsy-confirmed diagnosis of IgAN within the past 10 years prior to signature of the informed consent form (ICF). For participants with diabetes mellitus type 2, biopsy confirmation of IgAN diagnosis must be done within the past 24 months prior to signing the ICF.
An eGFR ≥ 30 mL/min/1.73m^2 at Screening as calculated using the 2021 chronic kidney disease epidemiology (CKD-EPI) creatinine formula. An eGFR of ≥ 20 and < 30 mL/min/1.73m^2 is acceptable for the cohorts 3 and 4.
Proteinuria of ≥ 1.0 gram per day (g/day) or UPCR ≥0.8 gram per gram (g/g) as assessed by an adequate 24-hour urine collection.
Clinically stable on a maximally tolerated dose or maximally approved dose of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) for at least 12 weeks prior to Screening, or intolerant of ACEI or ARB. If intolerant, this must be discussed with the Medical Monitor prior to randomization. Participants may also be using sodium-glucose cotransporter-2 inhibitors (SGLT2is), endothelin receptor antagonists (ERAs) approved for the treatment of IgAN, dual endothelin angiotensin receptor antagonist (DEARAs) approved for the treatment of IgAN, and/or mineralocorticoid receptor antagonists (MRAs) as long as the dose is stable for at least 12 weeks prior to Screening. Participants should remain on stable doses of these background medications for the duration of the study. Once the ICF is signed and thereafter, the doses cannot be changed during the study nor the drugs discontinued except if deemed related to an AE. Participants using sparsentan will not be permitted to use simultaneous ACEI or ARB medication.
Exclusion Criteria
Secondary forms of IgAN, indicated by the presence of any other systemic disease potentially leading to IgA deposits as determined by the Investigator.
History of rapidly progressive variant of IgAN, defined as eGFR loss by > 50% per 3 months and not explained by changes in renin-angiotensin system (RAS) blockade or other factors.
Nephrotic syndrome presumed to be due to minimal change disease (MCD) variant.
Concomitant other progressive glomerulonephritis or non-immunologic glomerular disease such as diabetic nephropathy.
Type 2 diabetes mellitus with Hemoglobin A1c (HbA1c) > 8% at Screening, or evidence of diabetic nephropathy on biopsy, history of diabetic microvascular or macrovascular disease (eg, diabetic retinopathy, peripheral neuropathy).
Any diagnosed or suspected immunosuppressed or immunodeficient state such as asplenia, human immunodeficiency virus (HIV), primary immunodeficiencies, organ or bone marrow transplantation, with the exception of corneal transplants.
Previously treated with immunosuppressive or other immunomodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (> 7.5 milligrams per deciliter [mg/d] prednisone/prednisolone equivalent) within 4 months (or 12 months for rituximab) prior to Screening.
Participants currently treated with oral budesonide. Participants who have stopped this therapy ≥ 4 months prior to Screening may be eligible.
Active clinically significant infections, known history of recurrent clinically significant infection, or Screening laboratory evidence consistent with an active infection, or IV anti-infectives (antibacterials, antiviral or antifungals). Participants with a history of opportunistic infections are excluded.
Hypogammaglobulinemia: Serum Immunoglobin G (IgG) < 6.0 gram per litre (g/L), at Screening.
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
454 participants
